Mallika Singh

Company: Revolution Medicines

Job title: VP, Translational Research

Seminars:

Panel Discussion – Clinical Program Development Takeaways: How Can Researchers & Drug Developers in Any Targeted, Immune, Chemo, ADC Therapies Unite & Collaborate Future Directions to Optimize Our Own Drugs & Overall Patient Outlook? 11:30 am

Learnings from the past, how have we each developed our drugs considering previous work published? How can we optimize our program for any of the GI Cancer Indications? Thoughts on translating an established candidate from another solid tumor into GI cancer Utilizing patient groups, precision oncology & early detection in our clinical programsRead more

day: Day Two

Targeting RAS Mutant GI Cancers – Treatment Strategies and Resistance Mechanisms 9:30 am

Unmet medical need in RAS mutant GI cancers RAS(ON) Targeted Therapies for RAS mutant GI cancers: mutantselective and RASMulti inhibitors Application of biomarker-driven combination strategiesRead more

day: Day Two